Ligand has assembled one of the largest and most diverse portfolios in the biotech and pharmaceutical industry. Our partners and licensees fund the development and commercialization of our portfolio and we are entitled to receive royalties and milestones on program success. Currently approved portfolio drugs include those that treat cancer, osteoporosis, fungal infections and low blood platelets, among others. Our partners and licensees have programs currently in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others.View Portfolio
Ligand has identified six drugs from the portfolio that stand out due to potential market size of indication, upcoming milestone events and/or potentially significant deal economics.
FSGS - Kidney Disease
|Phase II||Low double digits to mid-teens|
Ligand has assembled one of the largest portfolios of assets among our peers that covers a diverse array of indications.
Ligand has established alliances with the world's leading pharmaceutical companies.